Therapeutic Potential of Janus-Activated Kinase-2 Inhibitors for the Management of Myelofibrosis

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-2836
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Janus Kinase Inhibitors for Autoimmune Disorders

Prescriber
Pharmacology
2017English

Janus Kinase V617F Mutation Detection in Patients With Myelofibrosis

Balkan Journal of Medical Genetics
Genetics
2019English

Development of Selective Covalent Janus Kinase 3 Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

Janus Kinase-2 (JAK-2)

Science-Business eXchange
2011English

Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Therapeutic Potential of JAK2 Inhibitors

The Journal of OncoPathology
2013English

The Therapeutic Potential of Deubiquitinating Enzyme Inhibitors

Biochemical Society Transactions
Biochemistry
2010English

Prognostic and Therapeutic Potential of Adenylate Kinase 2 in Lung Adenocarcinoma

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy